Platelet-Derived NO in Subjects Affected by Type 2 Diabetes with and without Complications: Is there any Relationship with their Offspring?

Abstract

Aims

Macro- and microvascular complications are currently the principal causes of morbidity and mortality in patients with diabetes mellitus. Aim of this study was to determine if type 2 diabetic patients with nephropathy and coronary artery disease showed altered platelet-derived nitric oxide (NO) production, compared with diabetic subjects without complications, and if this alteration is also present in their diabetic offspring.

Methods

In this case-control observational study, platelet NO and peroxynitrite content was determined on plasma from 60 male adult type 2 diabetic patients and 60 male offspring type 2 diabetic patients. Plasmatic levels of homocysteine were also determined in the same individuals. Moreover, Western blot analysis of platelet lysates was performed with specific monoclonal antibody for endothelial (eNOS) and inducible (iNOS) nitric oxide synthase.

Results

Our study showed a lower piastrinic production of NO in the group of parents without complications (ADH), compared with the group of offspring without complications (YDH) and with the groups of parents with complications. Furthermore, we observed a lower synthesis of peroxynitrite in platelets from the ADH group than in the groups of patients with complications, and in the YDH group compared with all other groups. Subjects from YDH group also showed lower iNOS expression, compared with all other groups.

Conclusions

Our data suggest that alterations in nitric oxide metabolism may represent potential risk factors in type 2 diabetes complications, such as nephropathy and cardiovascular diseases, leading to development of new therapeutic strategies in order to delay and prevent the onset of such complications.

Key words

coronary artery disease - diabetic nephropathy - oxidative stress - peroxynitrite

• References

• 1 Grover-Paez F, Zavalza-Gomez AB. Endothelial dysfunction and cardiovascular risk factors. Diabetes research and clinical practice 2009; 84: 1-10
• 2 Bekyarova GY, Ivanova DG, Madjova VH. Molecular mechanisms associating oxidative stress with endothelial dysfunction in the development of various vascular complications in diabetes mellitus. Folia medica 2007; 49: 13-19
• 3 Eringa EC, Serne EH, Meijer RI. et al. Endothelial dysfunction in (pre)diabetes: Characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Reviews in endocrine & metabolic disorders 2013; 14: 39-48
• 4 Fleming I, Busse R. NO: the primary EDRF. Journal of molecular and cellular cardiology 1999; 31: 5-14
• 5 Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Archiv: European journal of physiology 2010; 459: 923-939
• 6 Forstermann U, Sessa WC. Nitric oxide synthases: Regulation and function. European heart journal 2012; 33: 829-837 837a–837d
• 7 Li H, Horke S, Förstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014; 237: 208-219
• 8 Triggle CR, Ding H. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. Journal of the American Society of Hypertension 2010; 4: 102-115
• 9 Tannous M, Rabini RA, Vignini A. et al. Evidence for iNOS-dependent peroxynitrite production in diabetic platelets. Diabetologia 1999; 42: 539-544
• 10 Rabini RA, Staffolani R, Fumelli P. et al. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia 1998; 41: 101-104
• 11 Mao S, Xiang W, Huang S. et al. Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus. Clinica chimica acta; international journal of clinical chemistry 2014; 431: 206-210
• 12 Pastore A, Noce A, Di Giovamberardino G et al. Homocysteine, cysteine, folate and vitamin B status in type 2 diabetic patients with chronic kidney disease. Journal of nephrology 2014
• 13 Levey AS, de Jong PE, Coresh J. et al. The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney international 2011; 80: 17-28
• 14 Rao GH. Measurement of ionized calcium in normal human blood platelets. Analytical biochemistry 1988; 169: 400-404
• 15 Vignini A, Nanetti L, Moroni C. et al. Modifications of platelet from Alzheimer disease patients: A possible relation between membrane properties and NO metabolites. Neurobiology of aging 2007; 28: 987-994
• 16 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry 1976; 72: 248-254
• 17 Kooy NW, Royall JA, Ischiropoulos H. Oxidation of 2',7'-dichlorofluorescin by peroxynitrite. Free radical research 1997; 27: 245-254
• 18 Boulos C, Jiang H, Balazy M. Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues. The Journal of pharmacology and experimental therapeutics 2000; 293: 222-229
• 19 Minniti G, Piana A, Armani U. et al. Determination of plasma and serum homocysteine by high-performance liquid chromatography with fluorescence detection. Journal of chromatography A 1998; 828: 401-405
• 20 DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes care 1991; 14: 173-194
• 21 Luscher TF. Mechanisms of disease: Paracine effects of adipose tissue, progenitor cell function, and epigenetics of diabetic vascular disease. European heart journal 2015; 36: 765-767
• 22 Ishii N, Patel KP, Lane PH. et al. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001; 12: 1630-1639
• 23 Moresco RN, Sangoi MB, De Carvalho JA. et al. Diabetic nephropathy: Traditional to proteomic markers. Clinica chimica acta; international journal of clinical chemistry 2013; 421: 17-30
• 24 Toth-Manikowski S, Atta MG. Diabetic kidney disease: Pathophysiology and therapeutic targets. J Diabetes Res 2015; 2015: 697010
• 25 Cipriani P, Kim SL, Klein JD. et al. The role of nitric oxide in the dysregulation of the urine concentration mechanism in diabetes mellitus. Front Physiol 2012; 3: 176
• 26 Prolo C, Alvarez MN, Radi R. Peroxynitrite, a potent macrophage-derived oxidizing cytotoxin to combat invading pathogens. BioFactors 2014; 40: 215-225
• 27 Hoang HH, Padgham SV, Meininger CJ. L-arginine, tetrahydrobiopterin, nitric oxide and diabetes. Current opinion in clinical nutrition and metabolic care 2013; 16: 76-82
• 28 Crabtree MJ, Channon KM. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric oxide: Biology and chemistry/official journal of the Nitric Oxide Society 2011; 25: 81-88
• 29 van Etten RW, de Koning EJ, Verhaar MC. et al Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 2002; 45: 1004-1010
• 30 Hwang SY, Siow YL, Au-Yeung KK. et al Folic acid supplementation inhibits NADPH oxidase-mediated superoxide anion production in the kidney. American journal of physiology Renal physiology 2011; 300: F189-F198